Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
257.35M | 616.00M | 228.29M | 23.15M | 62.35M | Gross Profit |
230.37M | 526.37M | 153.97M | -31.92M | 12.11M | EBIT |
-228.51M | 252.64M | -10.16M | -139.72M | -82.32M | EBITDA |
-165.13M | 295.29M | 4.22M | -126.42M | -74.58M | Net Income Common Stockholders |
-177.08M | 229.25M | -11.18M | -119.79M | -68.52M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
512.93M | 1.11B | 805.39M | 848.40M | 999.94M | Total Assets |
1.11B | 1.19B | 858.31M | 897.73M | 1.05B | Total Debt |
54.23M | 4.98M | 10.04M | 15.88M | 20.77M | Net Debt |
-458.70M | -606.59M | -795.35M | -832.53M | -979.17M | Total Liabilities |
216.74M | 139.50M | 72.06M | 109.05M | 143.01M | Stockholders Equity |
894.94M | 1.05B | 786.24M | 788.68M | 907.30M |
Cash Flow | Free Cash Flow | |||
-316.33M | 302.25M | -44.38M | -144.84M | -104.81M | Operating Cash Flow |
-316.33M | 309.69M | -31.64M | -140.46M | -92.34M | Investing Cash Flow |
205.63M | -507.49M | -12.76M | -4.41M | -12.52M | Financing Cash Flow |
5.69M | 14.06M | -2.81M | -7.39M | -6.60M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | kr17.81B | 19.74 | 60.96% | ― | 501.62% | ― | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
52 Neutral | kr3.56B | 0.30 | -15.21% | ― | -75.91% | ― | |
50 Neutral | kr2.51B | ― | -45.80% | ― | -0.57% | -39.92% | |
47 Neutral | kr1.16B | ― | -42.24% | ― | ― | -19.44% | |
45 Neutral | kr2.19B | ― | -40.15% | ― | ― | 63.85% | |
42 Neutral | kr1.64B | ― | ― | 9.53% | 41.19% |
BioArctic AB held its Capital Markets Day 2025, outlining its strategic goals for 2030, which include expanding its pipeline, forming global partnerships, and launching Leqembi® for Alzheimer’s in the Nordics. The company aims to leverage its strong financial position, innovative research platforms, and successful partnerships to drive growth and profitability, positioning itself as a leading pharmaceutical entity in Sweden.
BioArctic AB announced the issuance of 3,000 Class B shares as part of its 2019/2028 stock option program, bringing the total number of shares to 88,531,485. This move reflects the company’s ongoing commitment to rewarding its stakeholders and maintaining a robust capital structure, with implications for its market positioning and shareholder engagement.
At its Annual General Meeting, BioArctic AB resolved to carry forward SEK 889,598,575 without paying dividends for 2024, re-elected its board members, and approved remuneration for them. The meeting also authorized the board to issue new shares and introduced a three-year incentive program for employees, which includes performance-based share units contingent on meeting specific conditions related to shareholder returns, operational targets, and sustainability goals.
BioArctic AB has received a positive opinion from the European Medicines Agency for orphan medicinal product designation for exidavnemab, a treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease. This designation provides incentives for developing treatments for rare diseases, potentially enhancing BioArctic’s market positioning and offering hope for addressing high unmet medical needs in MSA and related disorders.
BioArctic AB reported significant financial growth in Q1 2025, driven by the approval and commercial success of its Alzheimer’s treatment, Leqembi, in the EU and other markets. The company also benefited from a lucrative license agreement with Bristol Myers Squibb, contributing to a substantial increase in net revenues and operating profit, positioning BioArctic as a key player in the neurodegenerative disease treatment market.
Eisai, in partnership with BioArctic, projects significant revenue growth for their Alzheimer’s treatment, Leqembi, with sales expected to reach JPY 76.5 billion for fiscal year 2025. This growth reflects a 73% increase from the previous year, generating substantial royalties for BioArctic and strengthening their market position in Alzheimer’s treatment.
BioArctic AB will release its first quarter report for 2025 on May 21, inviting investors, analysts, and media to an audiocast and teleconference where the CEO and CFO will present and discuss the results. This event reflects BioArctic’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market perception and investor relations.
BioArctic AB has expanded its Phase 2a EXIST study to include Multiple System Atrophy (MSA) patients, following regulatory approval in Spain and Poland. This expansion marks a significant step in developing exidavnemab, a monoclonal antibody targeting alpha-synuclein aggregates, as a potential treatment for MSA and Parkinson’s, addressing a high unmet medical need in neurodegenerative diseases.